Home › Compound Library › Ipamorelin

Ipamorelin

Peptideiv · inferred

Highly selective growth hormone secretagogue (GHS) pentapeptide that mimics ghrelin at the GHS receptor. Terminal half-life ~2 hours with clearance of 0.078 L/h/kg. Unlike GHRP-6, does not significantly affect cortisol, prolactin, or appetite. Produces a clean GH pulse peaking at ~40 min. Typically dosed 200-300 mcg SC 2-3x/day.

Projected serum levels — 200 mcg (≈ 0.20 mg), twice daily

Ipamorelin
Ipamorelin modeled serum levels, 200 mcg (≈ 0.20 mg) twice daily over 15 days Population-based pharmacokinetic estimate. Steady state reached after approximately 1 days. 0 0.25 0.50 0.75 1 Day 0 Day 4 Day 7 Day 11 Day 15 Time on a regular schedule ≈ steady state · day 1

Maintenance schedule: 200 mcg (≈ 0.20 mg) twice daily (iv).

Modeled steady state after ~1 days: peak ≈ 0.075 mg, trough ≈ 0.002 mg body load. Population-based estimate over 15 days for a reference dose at a 70 kg reference body mass — the interactive app scales curves to your doses, timing, and body mass.

Key facts

Category
Peptide
Route modeled
IV
Model confidence
inferred
Half-life
2 h
Common dose
200 mcg (≈ 0.20 mg)
Suggested maximum
600 mcg/day
Reference dose range
100–600 mcg (single dose)
Suggested cadence
twice daily

Documented interactions

  • caution
    GHRP-2 (Pralmorelin) + Ipamorelin Potentiation

    Both are GH secretagogues acting on similar pathways. Stacking provides diminishing returns.

  • caution
    GHRP-6 + Ipamorelin Potentiation

    Both are GH secretagogues. Stacking provides diminishing returns.

  • watch
    Ibutamoren (MK-677) + Ipamorelin Stacked effects

    Ibutamoren (MK-677) and Ipamorelin both push the ghrelin receptor in the same direction.

Serum checks 5 modeled interaction pairings for ipamorelin across your whole stack — absorption conflicts, enzyme inhibition, and nutrient depletion included.

Research behind this entry

  1. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers Gobburu JVS et al. · Pharmaceutical Research, 1999 DOI

    First human PK/PD study of ipamorelin establishing a terminal half-life of 2 hours, clearance of 0.078 L/h/kg, Vdss of 0.22 L/kg, and dose-dependent GH release peaking at 0.67 hours.

  2. Pharmacokinetic evaluation of ipamorelin and other peptidyl growth hormone secretagogues with emphasis on nasal absorption Johansen PB et al. · Xenobiotica, 1998 DOI

    Comparative PK study (PMID:9879640) showing ipamorelin has lower systemic clearance than GHRP-6 and limited nasal bioavailability, supporting its greater selectivity and longer GH stimulation duration.

  3. Growth hormone secretagogues: history, mechanism of action, and clinical development Ishida J et al. · JCSM Rapid Communications, 2020 DOI

    Comprehensive review of GHS history including ipamorelin, covering the ghrelin receptor mechanism, selectivity profiles, and clinical development of GH secretagogues.

3 published studies referenced in the app, each with a plain-language summary.